U.S. Markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.3273%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.0736%)
     
  • USD/JPY

    135.1700
    +0.2370 (+0.1756%)
     
  • BTC-USD

    21,254.13
    +24.94 (+0.12%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

ICU Medical, Inc. Announces Third Quarter 2021 Results

  • Oops!
    Something went wrong.
    Please try again later.
·12 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN CLEMENTE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended September 30, 2021.

Third Quarter 2021 Results

Third quarter 2021 revenue was $336.1 million, compared to $318.6 million in the same period last year. GAAP gross profit for the third quarter of 2021 was $127.8 million, as compared to $113.9 million in the same period last year. GAAP gross margin for the third quarter of 2021 was 38%, as compared to 36% in the same period last year. GAAP net income for the third quarter of 2021 was $31.1 million, or $1.43 per diluted share, as compared to GAAP net income of $25.0 million, or $1.16 per diluted share, for the third quarter of 2020. Adjusted diluted earnings per share for the third quarter of 2021 were $2.07 as compared to $1.90 for the third quarter of 2020. Also, adjusted EBITDA was $71.9 million for the third quarter of 2021 as compared to $62.2 million for the third quarter of 2020.

Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Third quarter results were generally in line with our expectations.”

Revenues by product line for the three and nine months ended September 30, 2021 and 2020 were as follows (in millions):

Three months ended
September 30,

Nine months ended
September 30,

Product Line

2021

2020

$ Change

2021

2020

$ Change

Infusion Consumables

$

144.9

$

116.1

$

28.8

$

407.5

$

350.6

$

56.9

Infusion Systems

90.7

88.4

2.3

259.7

267.9

(8.2

)

IV Solutions*

89.2

101.9

(12.7

)

271.8

295.4

(23.6

)

Critical Care

11.3

12.2

(0.9

)

36.8

36.7

0.1

$

336.1

$

318.6

$

17.5

$

975.8

$

950.6

$

25.2

*IV Solutions includes $7.9 million and $32.2 million of contract manufacturing to Pfizer for the three and nine months ended September 30, 2021, respectively, as compared to $15.8 million and $44.8 million for the three and nine months ended September 30, 2020, respectively.

Conference Call

The Company will host a conference call to discuss third quarter 2021 financial results, today at 4:30 p.m. EDT (1:30 p.m. PDT). The call can be accessed at (877) 407-3982 or international (201) 493-6780. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical, Inc.

ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medical products used in infusion therapy, and critical care applications. ICU Medical's product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical, Inc. can be found at www.icumed.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as ''will,'' ''expect,'' ''believe,'' ''could,'' ''would,'' ''estimate,'' ''continue,'' ''build,'' ''expand'' or the negative thereof or comparable terminology, and may include (without limitation) information regarding the Company's expectations, goals or intentions regarding the future. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to, decreased demand for the Company's products, decreased free cash flow, the inability to recapture conversion delays or part/resource shortages on anticipated timing, or at all, changes in product mix, increased competition from competitors, lack of growth or improving efficiencies, unexpected changes in the Company's arrangements with its largest customers, the impact of the ongoing COVID-19 pandemic on the Company and our financial results and the Company’s ability to successfully close and subsequently integrate the pending Smiths Medical acquisition. Future results are subject to risks and uncertainties, including the risk factors, and other risks and uncertainties, described in the Company's filings with the Securities and Exchange Commission, which include those in the Company's most recent Annual Report on Form 10-K and our subsequent filings. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.


ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)

September 30,
2021

December 31,
2020

(Unaudited)

(1)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$

519,485

$

396,097

Short-term investment securities

18,009

14,687

TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES

537,494

410,784

Accounts receivable, net of allowance for doubtful accounts

116,043

124,093

Inventories

291,601

314,928

Prepaid income taxes

31,381

29,480

Prepaid expenses and other current assets

34,718

41,492

TOTAL CURRENT ASSETS

1,011,237

920,777

PROPERTY AND EQUIPMENT, net

458,041

466,628

OPERATING LEASE RIGHT-OF-USE ASSETS

40,979

46,571

LONG-TERM INVESTMENT SECURITIES

7,172

12,974

GOODWILL

32,760

33,001

INTANGIBLE ASSETS, net

192,778

197,231

DEFERRED INCOME TAXES

35,585

31,034

OTHER ASSETS

60,799

55,475

TOTAL ASSETS

$

1,839,351

$

1,763,691

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:

Accounts payable

$

62,008

$

71,864

Accrued liabilities

94,133

97,021

Income tax payable

2,636

303

Contingent earn-out liability

26,300

26,300

TOTAL CURRENT LIABILITIES

185,077

195,488

CONTINGENT EARN-OUT LIABILITY

3,100

OTHER LONG-TERM LIABILITIES

40,853

47,835

DEFERRED INCOME TAXES

1,663

1,663

INCOME TAX PAYABLE

18,686

16,440

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY:

Convertible preferred stock, $1.00 par value Authorized—500 shares; Issued and outstanding— none

Common stock, $0.10 par value — Authorized, 80,000 shares; Issued — 21,238 shares at September 30, 2021 and 21,058 at December 31, 2020 and outstanding 21,238 shares at September 30, 2021 and 21,058 shares at December 31, 2020

2,124

2,106

Additional paid-in capital

711,152

693,068

Treasury stock, at cost

(48

)

(39

)

Retained earnings

891,862

808,652

Accumulated other comprehensive loss

(15,118

)

(1,522

)

TOTAL STOCKHOLDERS' EQUITY

1,589,972

1,502,265

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

1,839,351

$

1,763,691

______________________________________________________
(1) December 31, 2020 balances were derived from audited consolidated financial statements.


ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In thousands, except per share data)

Three months ended
September 30,

Nine months ended
September 30,

2021

2020

2021

2020

TOTAL REVENUES

$

336,060

$

318,567

$

975,783

$

950,553

COST OF GOODS SOLD

208,269

204,643

611,783

608,930

GROSS PROFIT

127,791

113,924

364,000

341,623

OPERATING EXPENSES:

Selling, general and administrative

74,815

70,854

221,127

210,401

Research and development

12,238

10,126

34,332

31,151

Restructuring, strategic transaction and integration

2,358

4,114

8,994

22,903

Change in fair value of contingent earn-out

4,300

7,000

Contract settlement

(1,000

)

127

(975

)

TOTAL OPERATING EXPENSES

89,411

88,394

264,580

270,480

INCOME FROM OPERATIONS

38,380

25,530

99,420

71,143

INTEREST EXPENSE

(168

)

(616

)

(492

)

(1,583

)

OTHER (EXPENSE) INCOME, net

(287

)

1,252

921

(2,175

)

INCOME BEFORE INCOME TAXES

37,925

26,166

99,849

67,385

PROVISION FOR INCOME TAXES

(6,844

)

(1,180

)

(16,639

)

(6,657

)

NET INCOME

$

31,081

$

24,986

$

83,210

$

60,728

NET INCOME PER SHARE

Basic

$

1.47

$

1.19

$

3.93

$

2.91

Diluted

$

1.43

$

1.16

$

3.83

$

2.82

WEIGHTED AVERAGE NUMBER OF SHARES

Basic

21,214

20,948

21,189

20,870

Diluted

21,730

21,556

21,735

21,561

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). The non-GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. There are material limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled non-GAAP financial measures used by other companies, including peer companies. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods. We use non-GAAP financial measures in addition to and in conjunction with GAAP financial measures to analyze and assess the overall performance of our business, in making financial, operating and planning decisions, and in determining executive incentive compensation. The non-GAAP financial measures included in this press release are adjusted EBITDA and adjusted diluted earnings per share ("Adjusted Diluted EPS").

Adjusted EBITDA excludes the following items from net income:

Interest, net: We exclude interest in deriving adjusted EBITDA as interest can vary significantly among companies depending on a company's level of income generating instruments and/or level of debt.

Stock compensation expense: Stock-based compensation is generally fixed at the time the stock-based instrument is granted and amortized over a period of several years. The value of stock options is determined using a complex formula that incorporates factors, such as market volatility, that are beyond our control. The value of our restricted stock awards is determined using the grant date stock price, which may not be indicative of our operational performance over the expense period. Additionally, in order to establish the fair value of performance-based stock awards, which are currently an element of our ongoing stock-based compensation, we are required to apply judgment to estimate the probability of the extent to which performance objectives will be achieved. Based on the above factors, we believe it is useful to exclude stock-based compensation in order to better understand our operating performance.

Intangible asset amortization expense: We do not acquire businesses or capitalize certain patent costs on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition. Capitalized patent costs can vary significantly based on our current level of development activities. We believe that excluding amortization of intangible assets provides the users of our financial statements with a consistent basis for comparison across accounting periods.

Depreciation expense: We exclude depreciation expense in deriving adjusted EBITDA because companies utilize productive assets of different ages and the depreciable lives can vary significantly resulting in considerable variability in depreciation expense among companies.

Restructuring, strategic transaction and integration: We incur restructuring and strategic transaction charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our ongoing business. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our ongoing operations with prior and future periods.

Change in fair value of contingent earn-out: We exclude the impact of certain amounts recorded in connection with business combinations. We exclude items that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing.

Product-related charges: We exclude non-cash product-related charges in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Taxes: We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be non-core to the business and may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Adjusted Diluted EPS excludes from diluted EPS, net of tax, stock compensation expense, intangible asset amortization expense, restructuring, strategic transaction and integration, change in fair value of contingent earn-out and product-related charges. The tax effect on the above adjustments is calculated using the specific tax rate applied to each adjustment based on the nature of the item/or the tax jurisdiction in which the item has been recorded.

From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management.

The following tables reconcile our GAAP and non-GAAP financial measures:


ICU MEDICAL, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
(In thousands)

Adjusted EBITDA

Three months Ended
September 30,

2021

2020

GAAP net income

$

31,081

$

24,986

Non-GAAP adjustments:

Interest, net

(559

)

(142

)

Stock compensation expense

6,533

6,265

Depreciation and amortization expense

22,245

21,462

Restructuring, strategic transaction and integration

2,358

4,114

Change in fair value of contingent earn-out

4,300

Product-related charges

3,380

Provision for income taxes

6,844

1,180

Total non-GAAP adjustments

40,801

37,179

Adjusted EBITDA

$

71,882

$

62,165


Adjusted diluted earnings per share

Three months ended
September 30,

2021

2020

GAAP diluted earnings per share

$

1.43

$

1.16

Non-GAAP adjustments:

Stock compensation expense

$

0.30

$

0.29

Amortization expense

$

0.27

$

0.27

Restructuring, strategic transaction and integration

$

0.11

$

0.19

Change in fair value of contingent earn-out

$

$

0.20

Product-related charges

$

0.16

$

Estimated income tax impact from adjustments

$

(0.20

)

$

(0.21

)

Adjusted diluted earnings per share

$

2.07

$

1.90

CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Partner
(646) 277-1254